Non-alcoholic Steatohepatitis Treatment Market Size & Share 2024 to 2032

Non-alcoholic Steatohepatitis Treatment Market Size

Non-alcoholic Steatohepatitis Treatment Market size accounted for USD 5.5 billion in 2023 and is expected to grow at 29.9% of CAGR from 2024 to 2032. The market is driven by several factors, including the increasing prevalence of metabolic disorders, primarily due to the rising incidence of obesity and type 2 diabetes, as well as the growing awareness of NASH as a serious health condition.

For instance, according to a World Health Organization (WHO) report, in 2022, 43% of adults aged 18 years and above were overweight, and 16% were living with obesity worldwide, leading to a higher risk of developing NASH. This underscores the substantial burden of metabolic diseases on global health. Consequently, innovative treatment approaches, such as the development of new drug therapies and lifestyle intervention strategies focusing on weight loss and obesity management, have created new opportunities for enhancing patient care, thereby propelling market growth.
 

The non-alcoholic steatohepatitis (NASH) treatment market encompasses the development, production, and distribution of therapeutic solutions targeting NASH, a severe form of non-alcoholic fatty liver disease characterized by liver inflammation and damage caused by a buildup of fat in the liver.
 

Non-alcoholic Steatohepatitis Treatment Market Trends

The growth of the market is significantly driven by advancements in diagnostic techniques. Innovations in medical technology and diagnostic methods have enhanced healthcare professionals' ability to detect and monitor NASH more accurately and efficiently. These advancements have led to the development of less invasive and more precise diagnostic devices, which are critical for effectively managing the disease. For instance, a report by the American Association for the Study of Liver Diseases (AASLD) highlighted a 40% improvement in the accuracy of non-invasive diagnostic tools between 2010 and 2020.
 

This improvement has enabled the early identification of NASH in many patients, facilitating timely intervention and treatment. These diagnostic advancements have not only raised the standards of NASH care but also significantly increased the number of liver disease diagnoses, thereby driving the demand for effective therapeutic solutions. The improved detection capabilities have encouraged more patients to seek medical advice and treatment, thus contributing to the expansion of the NASH treatment market.
 

Non-alcoholic Steatohepatitis Treatment Market Analysis

Based on drug type, the market is segmented into vitamin E & Pioglitazone, obeticholic acid (OCA), semaglutide, selonsertib, cenicriviroc, and other drug types. The vitamin E & Pioglitazone segment dominated the market with USD 1.7 billion in 2023.
 

• Vitamin E plays an important role in the treatment of non-alcoholic steatohepatitis (NASH), primarily due to its antioxidant properties, which help mitigate liver inflammation and damage. In addition, pioglitazone, a drug from the thiazolidinedione class, has shown promise in the treatment of NASH, especially for patients with concurrent type 2 diabetes.
   
• Moreover, as an affordable and generally safe option, vitamin E is recommended for NASH patients, thereby contributing to market growth.
   
• Furthermore, pioglitazone enhances insulin sensitivity and has demonstrated efficacy in improving liver histology in NASH patients, particularly those with diabetes.

Learn more about the key segments shaping this market

Download Free PDF

Based on route of administration, the non-alcoholic steatohepatitis treatment market is divided into oral and injectable. The oral segment accounted for significant market share of 63.6% in 2023.
 

• The oral route of administration is a predominant segment in the treatment of non-alcoholic steatohepatitis (NASH). Oral medications offer several advantages, such as ease of administration, patient compliance, and cost-effectiveness, making them a preferred choice in NASH therapy.
   
• Furthermore, the market is experiencing a surge in the development and approval of new oral therapeutic agents that target different pathways involved in the pathogenesis of NASH, including metabolic, anti-inflammatory, and antifibrotic pathways.
   

Based on the distribution channel, the non-alcoholic steatohepatitis treatment market is segmented into hospital pharmacies, retail and specialty pharmacies, and other distribution channels. The retail and specialty pharmacies segment dominated the market with USD 2.7 billion in 2023.  
 

• The retail and specialty pharmacy segments play a significant role in the non-alcoholic steatohepatitis (NASH) treatment market. As the prevalence of NASH continues to rise, largely due to the global obesity epidemic and the increasing incidence of metabolic syndrome, the demand for effective therapies has surged.
   
• Retail pharmacies serve as the first point of contact for many patients seeking over-the-counter solutions or prescription medications to manage symptoms of NASH, such as fatigue and abdominal discomfort. These pharmacies ensure accessibility and affordability, which are critical for long-term treatment adherence in chronic conditions like NASH.
   
• Specialty pharmacies, on the other hand, focus on distributing complex medications that require special handling, administration, or monitoring. They provide a personalized approach, including patient education and adherence programs, which is essential for managing NASH's complex therapeutic regimens.

North America non-alcoholic steatohepatitis treatment market is expected to grow at 28.4% CAGR, to reach USD 23.2 billion by 2032.
 

• The growth of the U.S. non-alcoholic steatohepatitis (NASH) treatment market is driven by the increasing prevalence of NASH. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that about 24% of U.S. adults have NAFLD, and about 1.5% to 6.5% of U.S. adults have NASH.
   
• Additionally, NASH can lead to serious complications like cirrhosis and liver cancer if left untreated. Factors such as rising obesity rates, the increasing prevalence of type 2 diabetes, and sedentary lifestyles contribute to the growth of NASH in the U.S. Furthermore, the market has witnessed a surge in research and development activities aimed at discovering effective treatment options.
   

The UK’s non-alcoholic steatohepatitis treatment market is experiencing robust growth in market.
 

• The UK's market is poised for significant growth, driven by rising awareness of the disease, its complications, and the lack of approved pharmacological treatments. Non-alcoholic fatty liver disease (NAFLD) is a major health concern in the UK, with lifestyle factors such as obesity, diabetes, and high cholesterol levels contributing to the increasing prevalence of NASH.
   
• Furthermore, pharmaceutical companies are actively involved in research and development activities, as well as clinical trials, to develop treatments targeting various aspects of NASH, such as inflammation, fibrosis, and metabolic dysfunction. The National Health Service (NHS) and healthcare providers in the UK are also focusing on lifestyle interventions and early diagnosis to manage the condition effectively.
   

The Asia Pacific non-alcoholic steatohepatitis treatment market is witnessing substantial growth of 33.2% during the analysis period.
 

• The Asia-Pacific region is experiencing a growing incidence of non-alcoholic steatohepatitis (NASH), largely due to urbanization, changes in dietary habits, and a sedentary lifestyle. Countries like China, India, and Japan are particularly affected, with rising obesity rates and the increasing prevalence of type 2 diabetes contributing to the growing burden of NASH.
   
• Furthermore, healthcare systems in the region are increasingly recognizing the importance of early detection and intervention in NASH. Additionally, pharmaceutical companies are exploring the Asia-Pacific market for clinical trials and drug development. The region’s diverse population and varying healthcare infrastructure present both challenges and opportunities for market expansion.
   

Non-alcoholic Steatohepatitis Treatment Market Share

The non-alcoholic steatohepatitis (NASH) treatment market is experiencing robust growth due to continuous innovation and technological advancements. This market expansion is fuelled by leading companies in the healthcare sector that are striving to provide a diverse range of advanced treatments, including both medications and innovative therapies. These companies are consistently investing in research and development to introduce new products and enhance existing ones.
 

Non-alcoholic Steatohepatitis Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are in the clinical development phase. The prominent players considered in the market are as mentioned below:

• AstraZeneca
• Bristol-Myers Squibb Company
• Conatus Pharmaceuticals
• Galmed Pharmaceuticals
• Genfit
• Gilead Sciences, Inc.
• Immuron Ltd
• Intercept Pharmaceuticals, Inc.
• Madrigal Pharmaceuticals
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• Zydus Cadila
   

Non-alcoholic Steatohepatitis Treatment Industry News:

• In March 2024, Madrigal Pharmaceuticals received U.S. FDA approval for Rezdiffra (resmetirom). This drug is used in the treatment of patients with non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. This strategy is expected to add value to the company’s business portfolio.
   
• In June 2022, Novo Nordisk and Echosens entered a strategic partnership aimed at addressing the challenges of underdiagnosis in NASH. By promoting non-invasive diagnostic solutions, the partnership aims to significantly improve early detection and diagnosis rates, potentially doubling them by 2025. This strategy helped the company to reach the untapped market and boost revenue.
   

The non-alcoholic steatohepatitis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Vitamin E & Pioglitazone
• Obeticholic acid (OCA)
• Semaglutide
• Selonsertib
• Cenicriviroc
• Other drug types

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Retail and specialty pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa